Weiner Zachary P, Crew Rebecca M, Brandt Kevin S, Ullmann Amy J, Schriefer Martin E, Molins Claudia R, Gilmore Robert D
Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA.
Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA
Clin Vaccine Immunol. 2015 Nov;22(11):1176-86. doi: 10.1128/CVI.00399-15. Epub 2015 Sep 16.
Laboratory testing for the diagnosis of Lyme disease is performed primarily by serologic assays and is accurate for detection beyond the acute stage of the infection. Serodiagnostic assays to detect the early stages of infection, however, are limited in their sensitivity, and improvement is warranted. We analyzed a series of Borrelia burgdorferi proteins known to be induced within feeding ticks and/or during mammalian infection for their utility as serodiagnostic markers against a comprehensive panel of Lyme disease patient serum samples. The antigens were assayed for IgM and IgG reactivity in line immunoblots and separately by enzyme-linked immunosorbent assay (ELISA), with a focus on reactivity against early Lyme disease with erythema migrans (EM), early disseminated Lyme neuroborreliosis, and early Lyme carditis patient serum samples. By IgM immunoblotting, we found that recombinant proteins BBA65, BBA70, and BBA73 reacted with early Lyme EM samples at levels comparable to those of the OspC antigen used in the current IgM blotting criteria. Additionally, these proteins reacted with serum samples from patients with early neuroborreliosis and early carditis, suggesting value in detecting early stages of this disease progression. We also found serological reactivity against recombinant proteins BBA69 and BBA73 with early-Lyme-disease samples using IgG immunoblotting and ELISA. Significantly, some samples that had been scored negative by the Centers for Disease Control and Prevention-recommended 2-tiered testing algorithm demonstrated positive reactivity to one or more of the antigens by IgM/IgG immunoblot and ELISA. These results suggest that incorporating additional in vivo-expressed antigens into the current IgM/IgG immunoblotting tier in a recombinant protein platform assay may improve the performance of early-Lyme-disease serologic testing.
莱姆病诊断的实验室检测主要通过血清学检测进行,对于感染急性期后的检测是准确的。然而,用于检测感染早期阶段的血清学诊断检测在敏感性方面存在局限性,需要改进。我们分析了一系列已知在蜱虫叮咬期间和/或哺乳动物感染期间诱导产生的伯氏疏螺旋体蛋白,以评估它们作为血清学诊断标志物针对莱姆病患者血清样本综合面板的效用。通过线性免疫印迹法以及分别通过酶联免疫吸附测定(ELISA)检测这些抗原的IgM和IgG反应性,重点关注针对伴有游走性红斑(EM)的早期莱姆病、早期播散性莱姆神经疏螺旋体病和早期莱姆心肌炎患者血清样本的反应性。通过IgM免疫印迹法,我们发现重组蛋白BBA65、BBA70和BBA73与早期莱姆EM样本的反应水平与当前IgM印迹标准中使用的OspC抗原相当。此外,这些蛋白与早期神经疏螺旋体病和早期心肌炎患者的血清样本发生反应,表明在检测该疾病进展的早期阶段具有价值。我们还通过IgG免疫印迹法和ELISA发现早期莱姆病样本与重组蛋白BBA69和BBA73存在血清学反应性。值得注意的是,一些经美国疾病控制与预防中心推荐的两级检测算法判定为阴性的样本,通过IgM/IgG免疫印迹法和ELISA显示出对一种或多种抗原的阳性反应性。这些结果表明,在重组蛋白平台检测中,将额外的体内表达抗原纳入当前的IgM/IgG免疫印迹层级,可能会提高早期莱姆病血清学检测的性能。